May 6 (Reuters) - Gossamer Bio ( GOSS ) said on Monday
it will collaborate with Chiesi Group to develop and
commercialize its drug seralutinib in multiple indications
related to blood pressure conditions.
Gossamer is to receive $160 million development
reimbursement payment and is eligible to receive up to $146
million in regulatory and $180 million in sales milestones as
part of the deal.